Recombinant AAV Capsid Peptide Insertion for Microglia Transduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for efficiently transducing microglia with recombinant adeno-associated viruses (rAAVs) are inadequate, leading to low transduction rates and insufficient transgene expression, and often trigger immune activation.
Innovation Solution
Development of recombinant AAV capsids with a seven-amino-acid peptide insertion that enhance transduction efficiency and minimize immune reactivation in microglia.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If existing AAV capsids are used for transducing microglia, then the viral vector can be constructed, but the transduction rate and transgene expression level remain extremely poor
Solution Approach 1:
The patent applies parameter changes by modifying the amino acid sequence of the AAV capsid protein through a seven-amino-acid peptide insertion. This structural parameter change creates new capsid variants (AAV-MG1, AAV-MG2, etc.) that have altered surface properties enabling efficient recognition and entry into microglia, thereby resolving the contradiction between transduction rate and transgene expression level
Solution Approach 2:
The patent creates composite viral vectors by combining the modified capsid protein (with peptide insertion) with the AAV genomic backbone. This composite structure integrates the enhanced microglial targeting capability of the modified capsid with the safe and efficient gene delivery properties of AAV, achieving both high transduction rate and sufficient transgene expression
2Productivity
If viral vectors are used to transduce microglia, then gene delivery can be achieved, but immune activation is triggered
Solution Approach 1:
The patent applies local quality by making a specific localized modification (seven-amino-acid peptide insertion) at a particular region of the capsid protein rather than globally altering the entire viral structure. This localized change provides microglial specificity while preserving the overall AAV structure that is known to be immunologically safe, thus achieving high gene delivery without triggering immune activation
Data Source
AI summary
Provided is a recombinant adeno-associated virus (rAAV) capsid protein, comprising an amino acid sequence of 11 contiguous amino acids X1X2X3X4X5X6X7X8X9X10Q, rAAV vector comprising the same, and the use thereof.